Holen Sie sich die Stockscreener-App
59.75
0.19%
0.08
Schlusskurs vom Vortag:
$59.67
Offen:
$59.58
24-Stunden-Volumen:
572.83K
Relative Volume:
0.28
Marktkapitalisierung:
$11.46B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
22.21
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+2.42%
1M Leistung:
+9.32%
6M Leistung:
-3.15%
1J Leistung:
-29.36%
1-Tages-Spanne:
$59.26
$60.29
1-Wochen-Bereich:
$56.48
$60.29
52-Wochen-Spanne:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.78 | 11.35B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
589.03 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.53 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha
BioMarin Pharmaceutical Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional
Is BioMarin Pharmaceutical Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What drives BioMarin Pharmaceutical Inc. stock priceAccelerated earnings growth - Autocar Professional
What analysts say about BioMarin Pharmaceutical Inc. stockDouble-digit growth - jammulinksnews.com
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - WV News
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize
BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria
What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks
BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com
The Best Biotech Stocks to Buy - Morningstar
BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com
BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener
BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan
BioMarin Announces Completion of Acquisition of Inozyme - ETX View
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index - MarketScreener
BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A - MSN
11 Most Undervalued US Stocks According to Analysts - Insider Monkey
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies - Reuters
BioMarin stock maintains Buy rating at Jefferies amid exclusivity battle - Investing.com
Landmark 5-Year Data: BioMarin Gene Therapy Transforms Hemophilia Treatment with 81% Success Rate - Stock Titan
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):